PDS Biotechnology (NASDAQ:PDSB) Shares Down 4% – What’s Next?

PDS Biotechnology Corporation (NASDAQ:PDSB) shares were down 4% during mid-day trading on Thursday . The company traded as low as $0.8275 and last traded at $0.8721. Approximately 1,023,373 shares traded hands during mid-day trading, an increase of 26% from the average daily volume of 812,523 shares. The stock had previously closed at $0.9085.

Wall Street Analyst Weigh In

PDSB has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. B. Riley cut their target price on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, November 25th. Finally, HC Wainwright increased their price target on PDS Biotechnology from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Trading Down 4.0%

The company has a market capitalization of $42.72 million, a P/E ratio of -1.06 and a beta of 1.12. The firm has a fifty day moving average price of $0.89 and a 200-day moving average price of $1.01. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.09 and a quick ratio of 2.09.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. On average, equities research analysts anticipate that PDS Biotechnology Corporation will post -1.2 earnings per share for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Inspirion Wealth Advisors LLC lifted its stake in shares of PDS Biotechnology by 338.5% during the 3rd quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock valued at $348,000 after buying an additional 265,862 shares in the last quarter. Squarepoint Ops LLC lifted its position in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares during the last quarter. Susquehanna International Group LLP grew its position in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after acquiring an additional 80,937 shares in the last quarter. Jane Street Group LLC purchased a new stake in PDS Biotechnology in the second quarter worth approximately $92,000. Finally, Marshall Wace LLP purchased a new stake in PDS Biotechnology during the 2nd quarter valued at about $91,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.